Form 4: Supernus Pharmaceuticals Executive Exercises and Disposes of Performance Share Units

Frank Mottola, SVP at Supernus Pharmaceuticals, reports the exercise and disposal of performance share units to cover tax obligations.

Summary

• On February 26, 2025, Frank Mottola, SVP at Supernus Pharmaceuticals, executed transactions involving performance share units.
• He exercised 2,010 performance share units and 3,750 performance share units, which converted into common stock.
• Simultaneously, he disposed of 976 shares and 1,909 shares of common stock at a price of $39.48 to satisfy tax withholding requirements.
• Following these transactions, Mottola directly owns 15,774 shares of Supernus Pharmaceuticals common stock.

Sentiment

Score: 5

Explanation: This is a neutral event. It reflects standard executive compensation practices and tax obligations.

Industry Context

This Form 4 filing is a routine disclosure of insider transactions, providing transparency into the actions of company executives. It is a standard practice for executives to exercise stock options or share units and then sell a portion of the acquired shares to cover tax liabilities.

Comparison to Industry Standards

• Form 4 filings are standard practice across publicly traded companies, including pharmaceutical firms like Supernus.
• The exercise of performance share units and subsequent sale for tax obligations is a common occurrence among executives in comparable companies.
• Companies like Teva Pharmaceuticals, Viatris, and Amneal Pharmaceuticals also have executives who regularly file Form 4s related to stock option exercises and sales.

Stakeholder Impact

• The transaction has a minimal direct impact on shareholders, as it is a routine executive compensation matter.
• Employees may view the vesting of performance share units as a positive aspect of the company's compensation structure.

Key Dates